InvestorsHub Logo
Followers 64
Posts 24028
Boards Moderated 0
Alias Born 11/23/2016

Re: boi568 post# 325691

Friday, 08/13/2021 3:12:18 AM

Friday, August 13, 2021 3:12:18 AM

Post# of 464902
Increasing the outstanding and issue shares is unquestionably dilution.

Dilution is not a nasty word, unexpected or in any way nefarious in context of this biotech company and it certainly isn’t to me, but it seems to be to some.

Missling is adding obligations with the cost more trial and presumably additional OLE patients without being able to know with certain if and when approval and commercialisation can take place.

Anavex is doing what is prudent and correct management.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News